Prostate cancer (PC) is the second most common cancer in older men， after skin cancer. PC is difficult to diagnose because the prostate-specific antigen screening method is associated with many false positives. In addition there is a need to develop new and more effective treatments. Among presently available new treatments， immunotherapy is a promising approach. We investigated the expression of the cancer/testis antigen， AKAP-4， in PC patients to evaluate the possibility of exploiting AKAP-4 as a target for immunotherapy.
Prostate cancer (PC) is the second most common cancer in older men， after skin cancer. PC is difficult to diagnose because the prostate-specific antigen screening method is associated with many false positives. In addition there is a need to develop new and more effective treatments. Among presently available new treatments， immunotherapy is a promising approach. We investigated the expression of the cancer/testis antigen， AKAP-4， in PC patients to evaluate the possibility of exploiting AKAP-4 as a target for immunotherapy.
